ARTICLE | Clinical News
Nolasiban: Ph III IMPLANT2 started
March 30, 2017 12:59 AM UTC
ObsEva began the double-blind, placebo-controlled, European Phase III IMPLANT2 trial to evaluate single doses of 900 mg oral nolasiban before fresh embryo transfer on day 3 or day 5 following egg retr...
BCIQ Target Profiles